rTMS Target Identification for Functional Disability in AUD+mTBI

Launched by VA OFFICE OF RESEARCH AND DEVELOPMENT · Jul 31, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option called repetitive transcranial magnetic stimulation (rTMS) for Veterans who have both alcohol use disorder and mild traumatic brain injury (AUD+mTBI). The goal is to find specific areas in the brain that are affected by these conditions and see if stimulating these areas can help improve daily functioning and recovery. rTMS has shown some promise in earlier studies, and this trial aims to better understand how these two conditions impact the brain to enhance treatment outcomes.

If you or someone you know is a Veteran between the ages of 18 and 65, can read and speak English, and has been diagnosed with alcohol use disorder and mild traumatic brain injury, you might be eligible to participate. However, there are certain exclusions, such as having a history of more severe brain injuries or certain mental health conditions. Participants will receive rTMS treatment and will be monitored throughout the trial to assess its effectiveness. This research is part of a larger effort to improve the rehabilitation and psychological health of Veterans, helping them lead more fulfilling lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Can read and speak English
• • Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for AUD
• • Symptom Attribution and Classification (SACA) criteria (Pape, Herrold et al 2016, JHTR) for mTBI (without requirement of clinical neuropsychological impairment)
• Exclusion Criteria:
• • History of moderate to severe TBI
• • Neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis)
• • History of or current psychotic spectrum disorders (i.e., schizophrenia, schizoaffective and bipolar disorders)
• • Intellectual disability (WTAR predicted full-scale IQ score \< 70)42
• • Are pregnant or nursing
• • Use of benzodiazepines, opiates, cocaine, or amphetamines in the past 30 days
• • Meet DSM-5 criteria for moderate to severe cannabis use disorder
• • Contraindications to MRI (e.g., claustrophobia, ferromagnetic metal in eyes or face, congestive heart failure, implanted cardiac pacemaker or defibrillator, cochlear implant, nerve stimulator)
• • Meet SACA criteria for 'Questionable Validity' of performance effort and symptom reporting